2022
DOI: 10.1016/j.bmc.2021.116521
|View full text |Cite
|
Sign up to set email alerts
|

Novel O-acylated (E)-3-aryl-6,7-dihydrobenzisoxazol-4(5H)-one oximes targeting HSP90-HER2 axis in breast cancer cells

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
3
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
5

Relationship

1
4

Authors

Journals

citations
Cited by 6 publications
(3 citation statements)
references
References 67 publications
0
3
0
Order By: Relevance
“…A large number of studies had shown that drugs to promote the apoptosis of cancer cells were one of the main strategies for the treatment of cancer [27,28] . Thus, we further analyzed whether compound 4a 7 could achieve antiproliferation effect by inducing HeLa cells apoptosis.…”
Section: Resultsmentioning
confidence: 99%
See 1 more Smart Citation
“…A large number of studies had shown that drugs to promote the apoptosis of cancer cells were one of the main strategies for the treatment of cancer [27,28] . Thus, we further analyzed whether compound 4a 7 could achieve antiproliferation effect by inducing HeLa cells apoptosis.…”
Section: Resultsmentioning
confidence: 99%
“…A large number of studies had shown that drugs to promote the apoptosis of cancer cells were one of the main strategies for the treatment of cancer. [27,28] Thus, we further analyzed whether compound 4a 7 could achieve antiproliferation effect by inducing HeLa cells apoptosis. Firstly, to determine the effect of compound 4a 7 on cell apoptosis, the morphological changes of HeLa cells treated with different concentrations of compound 4a 7 were observed using Hoechst 33258 staining assay.…”
Section: Cell Apoptosis Analysismentioning
confidence: 99%
“…Cell cycle distribution and apoptosis were analyzed as described previously [ 48 ]. MCF7 cells were seeded in 6-well plates in DMEM containing 10% FBS and treated with compounds 3d , 2d , and 1d for 24 h. Сell sediments were lysed in a buffer containing 50 µg/mL propidium iodide (Sigma-Aldrich), 100 µg/mL RNase A (Qiagen), 0.1% sodium citrate, and 0.3% NP-40 (Helicon) for 30 min in the dark at 4 °C.…”
Section: Methodsmentioning
confidence: 99%